scholarly journals Choroid Plexus Carcinoma: A Rare Tumor in Adult

2014 ◽  
Vol 05 (04) ◽  
pp. 146-149 ◽  
Author(s):  
Chi-Man Yip ◽  
Hui-Hwa Tseng ◽  
Shu-Shong Shu-Shong Hsu
2012 ◽  
Vol 03 (01) ◽  
pp. 71-73 ◽  
Author(s):  
Sanjeev Kishore ◽  
Gita Negi ◽  
Harsh Meena ◽  
Kusum Anuradha ◽  
Prakash Ved Pathak ◽  
...  

ABSTRACTChoroid plexus carcinoma is a very rare tumor in adults. Here we report a rare case of choroid plexus carcinoma in an adult patient. A 24-year-old male presented with a right temporal intraventricular tumor with a cystic component also extending up to the cortex. Histological examination revealed complex papillary structures and glandular spaces showing stratification and multilayering of cells with nuclear crowding and numerous mitotic figures and large areas of necrosis. The patient went through a complete search for a possible primary keeping in mind the differential diagnosis of metastatic carcinoma that is more common in adults but there was no evidence of any other tumor. Finally a diagnosis of choroid plexus carcinoma was rendered. Immunohistochemical analysis for p53 protein showed positivity. Choroid plexus carcinoma is exceptionally rare in adults but cases do occur.


2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii276-iii276
Author(s):  
Alexis Judd ◽  
Erin Wright ◽  
Sarah Rush

Abstract Choroid plexus carcinoma (CPC) and Atypical teratoid/rhabdoid tumor (ATRT) are aggressive, malignant brain cancers most commonly arising in children less than 3 years of age. These tumors often have genetic alterations in the tumor suppressor gene SMARCB1/INI1. Rhabdoid predisposition syndrome (RTPS) categorizes patients with germline mutations in SMARCB1 or SMARCA4, leading to a markedly increased risk of developing rhabdoid tumors. Both CPC and ATRT have been demonstrated in patients with these rhabdoid predisposition syndromes. In general, these tumors tend to have a poor prognosis. However, with the presence of a SMARCB1 mutation they may have improved overall survival. We present two interesting cases of siblings with maternally inherited SMARCB1 mutations: one a 21-month-old male who presented with an ATRT and another a 10 month old female who presented with a CPC. The ATRT was treated as per the Children’s Oncology Group study ACNS0333 with high dose chemotherapy and stem cell rescue as well as cranial radiation. The CPC was treated as per CPT-SIOP 2009 with etoposide, cyclophosphamide and vincristine. Unlike other patients with these aggressive tumors, both of these patients are alive without evidence of disease recurrence 8 and 7 years post therapy, respectively. Additional genomic testing on both tumors is currently pending in order to potentially identify other mutations that may impact survival. These cases further illustrate the similar profile of two very different tumors with improved overall survival that may be secondary to mutations in SMARCB1 in RTPS.


2009 ◽  
Vol 20 ◽  
pp. S92
Author(s):  
Pedro Figueiredo ◽  
Corinna Lohmann ◽  
Henrique Santos

2017 ◽  
Vol 39 (8) ◽  
pp. e473-e475 ◽  
Author(s):  
Matthew McEvoy ◽  
Nathan Robison ◽  
Peter Manley ◽  
Torunn Yock ◽  
Kristine Konopka ◽  
...  

2005 ◽  
Vol 64 (5) ◽  
pp. 391-397 ◽  
Author(s):  
Alexander R. Judkins ◽  
Peter C. Burger ◽  
Ronald L. Hamilton ◽  
Bette Kleinschmidt-DeMasters ◽  
Arie Perry ◽  
...  

2012 ◽  
Vol 2 (2) ◽  
pp. 49 ◽  
Author(s):  
Chihiro Kawakami ◽  
Akiko Inoue ◽  
Kimitaka Takitani ◽  
Motomu Tsuji ◽  
Kimiko Wakai ◽  
...  

We herein report a female child with choroid plexus carcinoma treated with standard dose of imatinib at disease recurrence. This patient failed initial twice-surgical resections, central nervous system (CNS) irradiation, and adjuvant chemotherapies and high-dose thiotepa and melphalan with auto peripheral blood stem cell rescue. Finally, imatinib treatment was undergone as a palliative setting, however the tumor did not reduce and the patient died of tumor bleedings. We consider that the reasons for the failure are as follows: i) adequate CNS level of imatinib were not obtained because of the blood brain barrier, ii) the lack of plateletderived growth factor receptor beta expression in our case may have a crucial role.


Sign in / Sign up

Export Citation Format

Share Document